QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases

HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland, October 9, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.

Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en

        

        Contacts: 
        QIAGEN 
        Public Relations 
        Dr. Thomas Theuringer 
        e-mail: pr@QIAGEN.com  
        +49-2103-29-11826


        Investor Relations 
        John Gilardi 
        e-mail: ir@QIAGEN.com  
        +49-2103-29-11711


        CENTOGENE 
        CEO's office 
        Doreen Niemann 
        e-mail: press@centogene.com  
        +49-381-203-652-181


 

SOURCE Qiagen N.V.